EGFR and chronic myelogenous leukemia, BCR-ABL1 positive: Inhibition of deregulated kinase activities by small molecule inhibitors has been proven to be an effective treatment for many types of diseases, including chronic myeloid leukemia [6], epidermal growth factor receptor (EGFR)-mutated [7,8], and ALK-rearranged NSCLC [9].